News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
740,711 Results
Type
Article (43812)
Company Profile (471)
Press Release (696414)
Multimedia
Podcasts (128)
Webinars (21)
Section
Business (209361)
Career Advice (2042)
Deals (36162)
Drug Delivery (126)
Drug Development (84000)
Employer Resources (174)
FDA (16725)
Job Trends (15196)
News (354281)
Policy (33297)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2665)
Accelerated approval (41)
Adcomms (29)
Allergies (158)
Alliances (51111)
ALS (189)
Alzheimer's disease (1749)
Antibody-drug conjugate (ADC) (356)
Approvals (16981)
Artificial intelligence (587)
Autoimmune disease (192)
Automation (45)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (199)
Biotechnology (330)
Bladder cancer (173)
Brain cancer (64)
Breast cancer (676)
Cancer (5187)
Cardiovascular disease (443)
Career advice (1730)
Career pathing (40)
CAR-T (300)
CDC (52)
Celiac Disease (2)
Cell therapy (808)
Cervical cancer (39)
Clinical research (71774)
Collaboration (1897)
Company closure (4)
Compensation (1244)
Complete response letters (73)
COVID-19 (2781)
CRISPR (107)
C-suite (953)
Cystic fibrosis (154)
Data (6696)
Decentralized trials (2)
Denatured (41)
Depression (154)
Diabetes (518)
Diagnostics (6826)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (286)
Drug pricing (200)
Drug shortages (29)
Duchenne muscular dystrophy (265)
Earnings (91919)
Editorial (62)
Employer branding (21)
Employer resources (153)
Events (121660)
Executive appointments (1036)
FDA (20023)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (26)
Funding (1602)
Gene editing (227)
Generative AI (47)
Gene therapy (683)
GLP-1 (1036)
Government (4782)
Grass and pollen (6)
Guidances (387)
Healthcare (19233)
HIV (70)
Huntington's disease (53)
IgA nephropathy (90)
Immunology and inflammation (285)
Immuno-oncology (73)
Indications (138)
Infectious disease (3075)
Inflammatory bowel disease (208)
Inflation Reduction Act (17)
Influenza (127)
Intellectual property (264)
Interviews (316)
IPO (16938)
IRA (53)
Job creations (3714)
Job search strategy (1441)
JPM (67)
Kidney cancer (18)
Labor market (89)
Layoffs (584)
Leadership (35)
Legal (8030)
Liver cancer (96)
Longevity (20)
Lung cancer (693)
Lymphoma (394)
Machine learning (47)
Management (59)
Manufacturing (864)
MASH (177)
Medical device (13961)
Medtech (14025)
Mergers & acquisitions (20341)
Metabolic disorders (1376)
mRNA (187)
Multiple sclerosis (176)
NASH (19)
Neurodegenerative disease (365)
Neuropsychiatric disorders (99)
Neuroscience (3120)
Neurotech (1)
NextGen: Class of 2026 (6771)
Non-profit (4590)
Now hiring (69)
Obesity (664)
Opinion (294)
Ovarian cancer (174)
Pain (221)
Pancreatic cancer (250)
Parkinson's disease (313)
Partnered (34)
Patents (529)
Patient recruitment (554)
Peanut (61)
People (60504)
Pharmaceutical (84)
Pharmacy benefit managers (31)
Phase 1 (22568)
Phase 2 (31646)
Phase 3 (23402)
Pipeline (6216)
Policy (314)
Postmarket research (2602)
Preclinical (9639)
Press Release (67)
Prostate cancer (267)
Psychedelics (57)
Radiopharmaceuticals (312)
Rare diseases (980)
Real estate (6067)
Recruiting (71)
Regulatory (25255)
Reports (53)
Research institute (2498)
Resumes & cover letters (355)
Rett syndrome (30)
RNA editing (21)
RSV (81)
Schizophrenia (159)
Series A (271)
Series B (205)
Service/supplier (11)
Sickle cell disease (109)
Special edition (27)
Spinal muscular atrophy (164)
Sponsored (43)
Startups (3809)
State (2)
Stomach cancer (19)
Supply chain (113)
Tariffs (85)
The Weekly (85)
Vaccines (1057)
Venture capital (98)
Weight loss (427)
Women's health (105)
Worklife (20)
Date
Today (168)
Last 7 days (684)
Last 30 days (3034)
Last 365 days (30861)
2026 (5937)
2025 (31064)
2024 (36295)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (92)
Alaska (7)
Arizona (327)
Arkansas (15)
Asia (40797)
Australia (6784)
California (12031)
Canada (3426)
China (1187)
Colorado (506)
Connecticut (523)
Delaware (350)
Europe (89596)
Florida (1789)
Georgia (379)
Hawaii (3)
Idaho (61)
Illinois (934)
India (74)
Indiana (547)
Iowa (24)
Japan (462)
Kansas (131)
Kentucky (45)
Louisiana (35)
Maine (73)
Maryland (1459)
Massachusetts (8747)
Michigan (340)
Minnesota (659)
Mississippi (6)
Missouri (134)
Montana (35)
Nebraska (29)
Nevada (129)
New Hampshire (85)
New Jersey (3209)
New Mexico (31)
New York (3142)
North Carolina (1592)
North Dakota (9)
Northern California (5901)
Ohio (355)
Oklahoma (21)
Oregon (45)
Pennsylvania (2408)
Puerto Rico (24)
Rhode Island (50)
South America (1122)
South Carolina (69)
South Dakota (1)
Southern California (4684)
Tennessee (191)
Texas (1850)
United States (42747)
Utah (359)
Vermont (1)
Virginia (283)
Washington D.C. (81)
Washington State (987)
West Virginia (4)
Wisconsin (120)
Wyoming (2)
740,711 Results for "neumora therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
February 4, 2026
·
1 min read
Press Releases
Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones
January 5, 2026
·
6 min read
Press Releases
Neumora Therapeutics to Participate in Upcoming Conferences in November 2025
November 4, 2025
·
1 min read
Press Releases
Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation
January 5, 2026
·
9 min read
Press Releases
Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
·
8 min read
Press Releases
Neumora Therapeutics to Host Virtual R&D Day on October 27
October 1, 2025
·
4 min read
Press Releases
Neumora Therapeutics to Participate in Upcoming Conferences in September 2025
September 3, 2025
·
1 min read
Press Releases
Neumora Therapeutics Announces Class-Leading Weight Loss Demonstrated with NMRA-215 in Preclinical Diet-Induced Obesity Model
October 27, 2025
·
5 min read
Press Releases
Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898
October 27, 2025
·
6 min read
Depression
Neumora’s Novel Depression Drug Strikes Out in First Pivotal Trial
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant failed to meet the primary and key secondary endpoint in the first of three identical Phase III studies.
January 2, 2025
·
2 min read
·
Heather McKenzie
1 of 74,072
Next
